Pharming Group N.V. (PHAR) Q1 2026 Earnings
PHAR·Reported May 7, 2026·Before market open
Pharming Group N.V. reported Q1 2026 revenue of $72.4M (-16.4% YoY), missed analyst consensus of $92.1M by $19.6M. Diluted EPS came in at $-0.07 (+68.2% YoY), missed the $0.05 consensus by $0.12.
Revenue
$72.4Mmissed by $19.6M
Consensus: $92.1MDiluted EPS
$-0.07missed by $0.12
Consensus: $0.05
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q1 2026 Earnings FAQ
Common questions about Pharming Group N.V.'s Q1 2026 earnings report.
Pharming Group N.V. (PHAR) reported Q1 2026 earnings on May 7, 2026 before market open.
Pharming Group N.V. reported revenue of $72.4M and diluted EPS of $-0.07 for Q1 2026.
Revenue missed the consensus estimate of $92.1M by $19.6M. EPS missed the consensus estimate of $0.05 by $0.12.
Compared to the same quarter a year prior, revenue declined 16.4% from $86.7M a year earlier and diluted EPS grew 68.2% from $-0.22.